CIAM
VRDN icon

Caitong International Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Caitong International Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$159K Sell
8,675
-56,305
-87% -$907K 0.02% 463
2026
Q1 		$1.27M Buy
64,980
+64,976
+1,624,400% +$1.93M 0.24% 94
2025
Q4 		$124 Buy
+4
New +$110 ﹤0.01% 1677
2025
Q3 		– Sell
-173
Closed -$2.42K – 2559
2025
Q2 		$2.42K Buy
173
+4
+2% +$54 ﹤0.01% 1322
2025
Q1 		$2.28K Sell
169
-4,269
-96% -$72.7K ﹤0.01% 1287
2024
Q4 		$85.1K Buy
+4,438
New +$96.5K 0.08% 282

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caitong International Asset Management's VRDN Position: Q2 2026 in Review

Caitong International Asset Management reduced its Viridian Therapeutics (VRDN) stake by 87% in Q2 2026, selling an estimated $907K and leaving 8,675 shares worth $159K. The position accounts for 0.02% of the portfolio, ranked #463.

Caitong International Asset Management first reported a position in VRDN in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.27M in Q1 2026. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Caitong International Asset Management held 8,675 shares of Viridian Therapeutics worth $159K as of Q2 2026.
  • Caitong International Asset Management sold 56,305 Viridian Therapeutics shares in Q2 2026, an estimated $907K.
  • Viridian Therapeutics made up 0.02% of Caitong International Asset Management's portfolio in Q2 2026, its #463 holding.
  • Caitong International Asset Management first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Caitong International Asset Management's Viridian Therapeutics position peaked at $1.27M in Q1 2026.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.